Compare DCI & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCI | BIO |
|---|---|---|
| Founded | 1915 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 8.0B |
| IPO Year | 2005 | 1994 |
| Metric | DCI | BIO |
|---|---|---|
| Price | $93.00 | $363.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $99.00 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 557.6K | 277.5K |
| Earning Date | 06-02-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | $2,583,200,000.00 |
| Revenue This Year | $4.58 | $2.74 |
| Revenue Next Year | $5.18 | $3.20 |
| P/E Ratio | $34.17 | ★ N/A |
| Revenue Growth | ★ 4.05 | 0.65 |
| 52 Week Low | $73.63 | $236.73 |
| 52 Week High | $112.84 | $365.00 |
| Indicator | DCI | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 72.22 |
| Support Level | $85.48 | $289.16 |
| Resistance Level | $94.26 | N/A |
| Average True Range (ATR) | 1.98 | 11.72 |
| MACD | -0.56 | 0.41 |
| Stochastic Oscillator | 29.74 | 92.31 |
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.